Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 17/20 | 0.50 |
| ▸ | MAOA | P21397 | 17/20 | 0.50 |
| ▸ | MAOB | P27338 | 17/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.42 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.42 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071239 | 0.83 | LMNA (0.51) | KDM1AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL10071237 | 0.82 | NPSR1 (0.46) | KDM1AMEN1CYP2C19KMT2A | |
| SCHEMBL10071236 | 0.82 | MEN1 (0.47) | KDM1AMEN1CYP2C19KMT2AALDH1A1 | |
| SCHEMBL10071235 | 0.82 | KDM1A (0.42) | KDM1AMEN1CYP2C19KMT2A | |
| SCHEMBL10071228 | 0.82 | KMT2A (0.50) | MEN1CYP2C19KMT2AALDH1A1LMNA | |
| SCHEMBL10071234 | 0.80 | HSD11B1 (0.38) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL10071238 | 0.78 | KDM1A (0.47) | KDM1AMAOAMAOBMEN1KMT2A | |
| SCHEMBL10071229 | 0.77 | NPSR1 (0.48) | MEN1CYP2C19KMT2AALDH1A1LMNA | |
| SCHEMBL3198171 | 0.74 | CYP2C19 (0.44) | KDM1AMAOAMAOBMEN1CYP2C19 | |
| SCHEMBL16032835 | 0.72 | ALDH1A1 (0.48) | MEN1CYP2C19KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110699-B2 | Cobalt-catalyzed asymmetric cyclopropanation of alkenes with α-nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | PPOX, IDH3A, HMOX2 | KDM1A 1406/4885MAOA 458/4885MAOB 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.